Vetr Crowd Sees Juno Therapeutics As A 5-Star Stock

• Shares of Juno Therapeutics Inc JUNO have gained more nearly 30 percent over the past three months but are lower by more than 10 percent over the past five days.
• Despite recent weakness in Juno's stock, the Vetr crowd upgraded the issue to four stars out of a possible five.
• In addition to the strongest stock rating, Vetr's crowd-sourced price target of $58.95 implies a potential upside of more than 16 percent.

Shares of Juno Therapeutics have lost more than 10 percent over the past five days but are still higher by nearly 30 percent over the past three months. The recent decline in Juno's stock isn't deterring the Vetr crowd. On Tuesday, the Vetr crowd upgraded Juno's stock to a five-star rating with a crowd-sourced price target of $58.95 – implying a potential upside of more than 16 percent. Seventy-one percent of the Vetr crowd's ratings are bullish while an approximate equal percentage of the crowd holds a bullish view on Kite Pharma Inc KITE – a peer that is also racing to launch an effective treatment for leukemia and other blood cancers, according to Reuters. Reuters added that both Juno and Kite have leased factories that they are retooling for future use. In the meantime, both companies are using contract manufacturers for batches of their experimental cells used in clinical trials. Given the similar ambitions of both companies, it appears the Vetr crowd is more optimistic in Juno's outlook, as Kite's stock is only rated three out of a possible five-stars. In addition, the crowd-sourced price target of $75.43 implies an upside of barely one percent in Kite's stock.